Loading…
XERS
Xeris Biopharma Holdings, Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic
$8.48-1.40%
Key metrics
- Market cap
- $1.55B
- P/E
- —
- Forward P/E
- 21.7x
- P/B
- —
- Dividend yield
- —
- EPS
- -$0.10
- ROE
- —
- Profit margin
- -5.12%
- Revenue growth
- +28.70%
- Beta
- 0.85
- 52-week high
- $10.08
- 52-week low
- $5.25
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- 435
- Chicago, United States
Company description provided by Yahoo Finance.